Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (avastin)

被引:84
作者
Finger, Paul T. [1 ]
机构
[1] New York Eye Canc Ctr, New York, NY 10065 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2008年 / 70卷 / 04期
关键词
avastin; bevacizumab; intravitreal; radiation; retinopathy;
D O I
10.1016/j.ijrobp.2007.11.045
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To report on bevacizumab treatment for radiation retinopathy affecting the macula. Patients and Methods: Twenty-one patients with radiation retinopathy (edema, hemorrhages, capillary dropout, and neovascularization) and a subjective or objective loss of vision were treated. Treatment involved intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) every 6-12 weeks. Treatment was discontinued at patient request or if there was no measurable response to therapy. Main outcome measures included best corrected visual acuity, ophthalmic examination, retinal photography, and angiography. Results: Bevacizumab treatment was followed by reductions in retinal hemorrhage, exudation, and edema. Visual acuities were stable or improved in 86% (n = 18). Three patients discontinued therapy. Each was legally blind before treatment (n = 1), experienced little to no subjective improvement (n = 2), or was poorly compliant (n = 2). Three patients (14%) regained 2 or more lines of visual acuity. No ocular or systemic bevacizumab-related side effects were observed. Conclusions: Intravitreal bevacizumab can be used to treat radiation retinopathy. In most cases treatment was associated with decreased vascular leakage, stabilization, or improved vision. An anti-vascular endothelial growth factor strategy may reduce tissue damage associated with radiation vasculopathy and neuropathy. (C) 2008 Elsevier Inc.
引用
收藏
页码:974 / 977
页数:4
相关论文
共 15 条
[1]  
ARCHER D B, 1991, Eye (London), V5, P239
[2]  
Conn Joseph, 2006, Mod Healthc, V36, P26
[3]   Vascular endothelial growth factor: Basic science and clinical progress [J].
Ferrara, N .
ENDOCRINE REVIEWS, 2004, 25 (04) :581-611
[4]   Anti-vascular endothelial growth factor bevacizumab (Avastin) for radiation retinopathy [J].
Finger, Paul T. ;
Chin, Kimberly .
ARCHIVES OF OPHTHALMOLOGY, 2007, 125 (06) :751-756
[5]   Anti-VEGF bevacizumab (Avastin®) for radiation optic neuropathy [J].
Finger, Paul T. .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2007, 143 (02) :335-338
[6]   Laser photocoagulation for radiation retinopathy after ophthalmic plaque radiation therapy [J].
Finger, PT ;
Kurli, M .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2005, 89 (06) :730-738
[7]   Palladium-103 plaque radiotherapy for choroidal melanoma: An 11-year study [J].
Finger, PT ;
Berson, A ;
Ng, T ;
Szechter, A .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (05) :1438-1445
[8]   Radiation therapy for choroidal melanoma [J].
Finger, PT .
SURVEY OF OPHTHALMOLOGY, 1997, 42 (03) :215-232
[9]  
FINGER PT, 2001, VITREORETINAL SURG T, P403
[10]   THE COMBINED EFFECT OF DIABETES AND IONIZING-RADIATION ON THE RETINAL VASCULATURE OF THE RAT [J].
GARDINER, TA ;
AMOAKU, WMK ;
ARCHER, DB .
CURRENT EYE RESEARCH, 1993, 12 (11) :1009-1014